An ever-increasing array of proteomics methods using targeted qualitative and quantitative approaches aimed at characterizing and quantifying posttranslational modifications has become feasible using high-performance LC-MS methodologies and current instrumentation. This has enabled the detection, characterization, and quantitation of proteins and their modifications, ranging from phosphorylation to glycosylation among many others on a global, proteomewide scale. For more comprehensive results, methods often leverage selective enrichment of a targeted substoichiometric modification using antibody or other affinity-based recognition techniques as well as a variety of chemical targeting techniques. Such enrichment mixtures are separated and analyzed by reversed-phase chromatography and high-sensitivity MS ([@B1], [@B2]). A unique group of membrane-associated intracellular proteins are posttranslationally modified at cysteine residues near their c-termini with either C15 (farnesyl) or C20 (geranylgeranyl) isoprenoid moieties via a thioether linkage. "Prenylation" of target proteins is necessary for their association with the plasma membrane and with membranes of cellular organelles and, thus, participates in specifying their cellular localization and function. Many of them are GTPase switches and play a central role in cell signaling, transport, and cytoskeletal rearrangement, among other activities. Examples include the RAS family: KRAS4A and 4B (human), Hras, and Nras. RAS proteins trigger cell growth through kinase cascades. Posttranslational modifications of these proteins including the enzymes involved in prenylation and other c-terminal processing have been described ([@B3][@B4]--[@B5]). Point mutations in the guanosine triphosphate/guanosine diphosphate-binding region of RAS proteins are known to play a causative role in a variety of human cancers; mutations may also be responsible for other metabolic problems associated with autism and other neurological disorders ([@B6], [@B7]).

Prenylation of protein targets occurs via enzymatic conversions catalyzed by one of three enzymes. Farnesyltransferase and GGTase I[^1^](#G1){ref-type="fn"} are responsible for all reactions involving proteins with a c-terminal "CAAX" motif. GGTase II catalyzes transfer of the C20 polyisoprene to substrate Rab and other proteins with various c-terminal cysteine motifs, including XXCC, XXCXC, XXCCX, XCCXX, XCXXX, and CCXXX where "X" is any amino acid ([@B8], [@B9]). Several accessory proteins are known to play roles in the interaction of GGTase II with its substrates ([@B10]). In addition to the preceding, some proteins, such as those belonging to the Ras family (*e.g.* Kras, Nras, and Hras) are predicted to contain palmitoyl or other fatty acyl groups attached through cysteine thioesters located in their c-terminal regions. The enzymatically catalyzed addition of farnesene (C15) or geranylgeranyl (C20) to cysteine residues located in the CAAX motif at the C terminus of target proteins is absolutely required for their normal cellular function and distribution at the plasma membrane and other membrane locations. Other mandatory enzymatic processing of these so-called "CAAX box" proteins includes enzymatic removal of the c-terminal "AAX" sequence catalyzed by Rce I and c-terminal methyl esterification of the resulting mature protein by isoprenylcysteine carboxymethyltransferase.

Prenylated proteins have been shown to be excluded from lipid raft structures in the plasma membrane ([@B11]), but some proteins such as Hras carry both prenyl and palmitoyl modifications, perhaps rendering their membrane associations more complex ([@B12]). Modifications of the c-terminal amino acid sequence of KRAS 4B were recently shown to exert a profound effect on its membrane interactions ([@B13]). Targeted farnesyl transferase inhibitors have been tested in a clinical setting against KRAS-mediated cancers. However, it was discovered that inhibition led to a cellular switch to geranylgeranylation of the protein, presumably by GGTase 1 ([@B14]), rendering the drugs ineffective in this setting, although other clinical targets such as the laminopathies ([@B15]) including Hutchinson-Gilford progeria syndrome have proven more promising in this regard.

Direct characterization of prenylation has been limited by the lack of suitable analytical approaches, although various labeling and capture strategies in tissue culture have been used ([@B16]), usually employing isotopically labeled isoprenoid precursors or covalent handles linked to precursors in cell culture systems ([@B17], [@B18]). Heretofore, direct isolation and characterization of prenyl proteins and their c-terminal peptides has proved to be particularly difficult due to several factors: (1) c-terminal peptides are unusually hydrophobic, rendering them poor candidates for standard (C18) reversed-phase separations. (2) Many of these proteins contain a large number of lysine and arginine residues near their c-terminus that are known to promote interaction with the inner leaflet of the plasma membrane ([@B4]) but, more importantly in this context, discourage the use of tryptic protein digestion since resulting peptides would be too short (and predicted to be singly charged) eliminating meaningful analysis by LC-MS/MS in many cases. As it is, many of these peptides such as the c-terminal (human) KRAS 4B chymotryptic peptide with 14 basic residues in a total of 25 amino acids present a unique analytical challenge. (3) Customized informatics (as described below) is required in order to effectively detect the presence of these peptides in database searches. 4. Up to now, there were no targeted or chemistry-based affinity methods for peptides containing the isoprene moiety. A recent report described an elegant labeling strategy with chemically reactive isoprenoid probes designed to produce reporter ions in MS in which a number of prenyl proteins and their c-terminal peptides were identified and characterized ([@B19]). However, to characterize these proteins and their various posttranslational modifications from tissue and particularly to enable protein analysis from normal and disease states, a method that can enrich natively modified protein is necessary.

We have approached this problem using selective membrane protein extraction coupled with a new method that enables targeted capture of prenylated proteins.

EXPERIMENTAL PROCEDURES
=======================

### 

#### Experimental Design and Statistical Rationale

This study details results obtained from four different mouse brain extracts, thus four biological replicates. Within each replicate, we analyzed total proteins captured (chymotryptic digest) as well as peptides eluted either by exposing the capture matrix to reducing conditions, nonpolar solvent, or a combination of the two.

MATERIALS AND METHODS
=====================

### 

#### Extraction and Processing of Prenylated Proteins from Mouse Brain Tissue

#### Mouse Brain Sample Preparation

Mice were housed in a 12-h light-dark cycle, and all studies were approved by the Institutional Animal Care and Use Committee at University of California San Francisco. Mouse brain tissue was dissected from adult mice and kept frozen in dry ice or liquid nitrogen. In each of the four experiments washed membranes were prepared from three mouse brains using a hypotonic, acidic buffer (0.01N HCl) to neutralize endogenous serine protease activity with mechanical disruption using a Dounce homogenizer as outlined in [Fig. S1](http://www.mcponline.org/cgi/content/full/RA120.001944/DC1). The homogenate (50 ml) was centrifuged at 10,000 × *g* for 10 min at 4 °C. The supernatant was discarded, membranes were resuspended in the same volume of 0.01N HCl, and the suspension centrifuged as above. After another wash with 0.01N HCl, membranes were extracted with 5 ml of RIPA extraction buffer (50 m[m]{.smallcaps} Tris base, 150 m[m]{.smallcaps} NaCl, 1% (w/v) Igepal-630, 12 m[m]{.smallcaps} sodium deoxycholate, 0.1% (w/v) sodium dodecyl sulfate, pH 7.6) for 1.5 h at 4 °C with end-over-end mixing. Extracted membranes were sedimented at 10,000 × *g* for 10 min at 4 °C, and a second extraction was performed under the same conditions for 1.5 h ([Fig. S1](http://www.mcponline.org/cgi/content/full/RA120.001944/DC1)). Following sedimentation of the extracted membranes as above, the two soluble extracts were combined, and the solution was adjusted to 10 m[m]{.smallcaps} tris carboxyethyl phosphine using a 1 [m]{.smallcaps} stock solution at 4 °C (this step reduces protein disulfide bonds and labile thioesters but leaves prenylated cysteine thioethers intact). A protein-containing precipitate immediately formed, and the suspension was incubated at 4 °C for 1 h. In order to block all free thiols, iodoacetamide solution in water (0.5 [m]{.smallcaps}) was added to achieve a final concentration of 10 m[m]{.smallcaps}, and the solution was incubated at room temperature in the dark for 30 min. Finally, the suspension was centrifuged at 10,000 × *g* for 10 min. Insoluble proteins were recovered and resuspended in 5 ml of a solution containing 8 [m]{.smallcaps} urea and 50 m[m]{.smallcaps}, pH 7.8; the supernatant (containing most of the RIPA buffer detergents) was discarded. Solubilized proteins were exchanged into the same buffer (8 [m]{.smallcaps} urea/50 m[m]{.smallcaps} ABC) using gel permeation chromatography on Sephadex G-25 to remove residual tris carboxyethyl phosphine and iodoacetamide.

#### Protein Capture and Targeted Peptide Strategy

Prenyl proteins were captured on thiopropyl Sepharose 6B as follows ([Fig. S2](http://www.mcponline.org/cgi/content/full/RA120.001944/DC1)). Thirty-five milligrams of lyophilized resin were suspended in 1 ml of water, and the suspension was gently mixed for 10 min. The swollen resin was then washed in a spin column using five rinses of 0.5 ml water followed by five rinses of 0.5 ml of 50 m[m]{.smallcaps} ABC. For each wash, the resin was thoroughly resuspended before centrifugation. The resin was then mixed with 1 mg of the urea-containing protein solution from the G25 column, and the mixture was incubated on an end-over-end mixer for 18 h at 4 °C. Unbound proteins were removed from the thiopropyl resin using a spin column followed by extensive washing using 0.5 ml volumes (x5) of the following: 6 [m]{.smallcaps} urea/50 m[m]{.smallcaps} ABC; 2m NaCl; 70% acetonitrile/0.1% formic acid in water; water, 50 m[m]{.smallcaps} ABC. The washed resin was then resuspended in 200 μl of 50 m[m]{.smallcaps} ABC. One microgram of chymotrypsin (Promega sequencing grade) was added to the suspension, and the mixture was incubated with vigorous mixing at 37 °C for 5--6 h. The resin was placed in the spin column and unbound chymotryptic peptides were isolated. The resin was washed with 100 μl of 0.1% formic acid, and the wash was combined with the released peptides. Unbound chymotryptic peptides were saved for analysis.

#### Peptide Elution with DTT Followed by 50% Acetonitrile

Prenylated peptides were released from the resin using a two-step method ([Fig. S2](http://www.mcponline.org/cgi/content/full/RA120.001944/DC1)). All separations were done using spin columns. In the first step (DTT elution), resin was incubated with 200 μl 50 m[m]{.smallcaps} ABC containing 10 m[m]{.smallcaps} DTT for 2 h at room temperature with mixing. This step cleaved the thiopyridine-protecting groups from the resin and released some prenylated peptides. Following incubation, the resin was separated from the DTT-eluted solution followed by a rinse with 100 μl of 0.1% formic acid in water (which was combined with the DTT-eluted peptides). The resin was then suspended in 200 μl of 50% acetonitrile/50% water containing 0.1% formic acid and incubated as above (50% ACN elution), and the suspension was mixed overnight at room temperature. The resin was rinsed with 100 μl of the same solution, and the rinse was combined with the eluted peptides from this step.

Peptides from the DTT and 50% ACN elutions were dried under vacuum, and dry material from each fraction was resuspended in 50 μl of 1% formic acid in water. Peptides were purified by removing salt and reagents using C18-containing pipette tips (OMIX, Agilent) and eluted from the tips using 50% acetonitrile, 0.1% formic acid in water. Eluted peptides were dried under vacuum and resuspended in 10% acetonitrile, 0.1% formic acid in water for analysis by LC-MS.

#### LC-MS Analysis

HCD data on samples were obtained using a Q Exactive Plus mass spectrometer (Thermo Scientific) equipped with a nano-Acquity UPLC system (Waters, Milford, MA). Peptides were fractionated on a 20 cm × 75 μm inner diameter Picofrit (New Objective) column packed with 3.5 micron, 100 Å pore size Kromasil C18 using linear gradients of solvents (defined in the figure legends) composed by mixing solvent A: water + 0.1% formic acid and solvent B: acetonitrile + 0.1% formic acid. EThcD data were acquired using a Fusion Lumos (Thermo Scientific) mass spectrometer. In this case, peptides were fractionated on a 15 cm Easyspray (Thermo Scientific), C18 column. All mass measurements were performed in the Orbitrap. The 10 most abundant multiply charged ions were computer selected for HCD analysis in the Q Exactive; the Fusion Lumos was programmed to select the top 20 most abundant ions. The trigger intensity was set to 2000. HCD and EThcD fragments were measured in the Orbitrap.

#### Prenyl Protein Database

In order to create a database of possible prenylated proteins, we first searched the *Mus musculus* protein database (UniProtKB.2015.12.1) using the known sequence motifs as templates using MS-Pattern in Protein Prospector (ref PMID:16401513). We then filtered this list to only those annotated as being prenylated according to Uniprot to give a total of 284 entries.

#### Database Searching

Peaklists were extracted using an in-house program and data were searched against the Uniprot *Mus musculus* database (73,955 entries, downloaded) (and concatenated with a randomized sequence for each entry) or against an in-house produced accession list (see below) using Protein Prospector (version 6.1.22). To allow for cleavage of the AAX motif at the C-terminal side of cysteine by RceI in addition to chymotryptic cleavage, the enzyme specificity searched was cleavage C-terminal to Phe, Tyr, Trp, Leu, or Cys, allowing for three missed cleavages and one end nonspecific because of the loose specificity of chymotrypsin. Farnesyl, geranylgeranyl, and their neutral losses, carbamidomethylation of cysteine, acetylation of protein N termini, oxidation of Met, cyclization of N-terminal Gln, and C-terminal methylation were allowed as variable modifications, with three modifications per peptide permitted. The required mass accuracy was 20 ppm for precursor ions, and 30 ppm for HCD and EThcD fragments. Spectra identified as representing peptides featuring a Cys-modification with a maximum E value of 0.05 and with a SLIP (site localization) score (ref PMID:21490164) of 5 were used as a starting point for further analysis. All prenylated peptide spectra were manually examined for quality and authenticity.

RESULTS
=======

Isoprenylated proteins associate with cellular membranes. We started our isolation procedure by preparing a crude membrane fraction from mouse brain tissue. Membranes were washed extensively to remove soluble proteins and then extracted to solubilize membrane proteins including prenylated species ([Fig. S1](http://www.mcponline.org/cgi/content/full/RA120.001944/DC1)). Initially, tryptic, and chymotryptic digests of the solubilized proteins were analyzed using one-dimensional LC-MS/MS. Protein Prospector was used to search peak lists using an in-house curated prenyl protein database (see methods section for construction) to speed processing. Many peptides derived from known prenylated proteins were identified in the searches (data not shown). However, like others (*e.g.* ([@B20])), we were unable to detect the c-terminal peptides containing the prenyl modifications from any of the proteins identified.

While attempting derivatization methods to convert the prenyl groups into sulfhydryl-containing moieties that could be enriched using thiopropyl Sepharose ([Fig. 1](#F1){ref-type="fig"}), we discovered that the beads were able to enrich underivatized prenylated proteins from complex mixtures. After overnight incubation of the resin with protein extracts, the resin was washed extensively to remove nonspecifically bound proteins. Treatment of resin-bound proteins with chymotrypsin released many peptides, including a large number from prenylated proteins, but almost no prenylated c-terminal peptides could be identified in the chymotryptic digest. However, we found that some prenylated peptides (along with other peptides from both prenyl and non-prenyl proteins) were released from the thiopropyl resin after incubation with 10 m[m]{.smallcaps} dithiothreitol. Elution with aqueous 50% acetonitrile containing 0.1% (v/v) formic acid released more peptides (see [Table I](#TI){ref-type="table"} and [Table II](#TII){ref-type="table"}), suggesting a noncovalent hydrophobic binding mechanism, which was disrupted either by cleavage of the disulfide bond on the resin by DTT or by treatment with elevated levels of organic solvent. Most of the peptides released in these elutions were not from prenyl proteins, as revealed by searches of the entire *Mus musculus* (UniProtKB.2015.12.1) database; prenyl proteins only represented about 3--5% of the total number identified. However, this represented a significant enrichment for prenylated species compared with a proteomic survey of the crude membrane extract as stated above and allowed detection of natively prenylated c-terminal peptides from a complex mixture for the first time. When the thiopropyl resin was pretreated with DTT before the protein capture step, no prenylated peptides were observed in the DTT or acetonitrile eluates (data not shown), indicating the thiopyridyl leaving group is required for the binding. When we tried experiments with a related resin containing a larger, more polar glutathione linker to a thiopyridyl group, this led to many fewer identifications of modified c-terminal regions. Therefore, the thiopyridyl group is not sufficient; the propyl group is also playing a role in the enrichment.

![Structure of the thiopyridyl-protected thiopropyl group on thiopropyl Sepharose.](zjw0062061310001){#F1}

###### List of c-terminal modified peptides identified in a representative experiment showing multiple types of modification on some c-termini

  Protein (Uniprot ID)                                                         Peptide sequence                   Mass       Charge                                C-terminal modifications
  ---------------------------------------------------------------------------- ---------------------------------- ---------- ------------------------------------- ------------------------------------------------------
  2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CN37)                          (Y)GKGKPVPIHGSRKGGAMQIC            574.0913   4+                                    Geranylgeranyl neutral loss
                                                                                                                  560.5804   3+                                    Farnesyl neutral loss; methyl
                                                                                                                  684.3722   3+                                    Methyl only; oxidation at 17
                                                                                                                  581.5941   4+                                    Geranylgeranyl neutral loss; oxidation at 17; methyl
                                                                                                                  577.5951   4+                                    Geranylgeranyl neutral loss; methyl
                                                                                                                  560.5804   4+                                    Farnesyl neutral loss
                                                                               (Y)YGKGKPVPIHGSRKGGAMQIC           614.858    4+                                    Geranylgeranyl neutral loss
                                                                                                                  601.3456   4+                                    Farnesyl neutral loss, methyl
  Laminin B1 (LMNB1)                                                           (F)HQQGAPRASNKSC                   401.2231   4+                                    Farnesyl neutral loss; methyl
                                                                                                                  529.9572   3+                                    Farnesyl neutral loss
  Laminin B2 (LMNB2)                                                           (F)HQQGDPRTTSRGC                   554.2924   3+                                    Farnesyl, methyl
  Cell division control protein 42 homolog (CDC42)                             (L)AALEPPEPKKSRRC                  467.7859   4+                                    Geranylgeranyl, methyl
                                                                                                                  618.7027   3+                                    Geranylgeranyl
                                                                                                                  596.0143   3+                                    Farnesyl
  Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 (GBG12)   (L)LMGIPTSENPFKDKKTC               549.5607   4+                                    Geranylgeranyl neutral loss; methyl
  (M)GIPTSENPFKDKKTC                                                           488.5303                           4+         Geranylgeranyl neutral loss; methyl   
  Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7 (GBG7)     (H)ARNDPLLVGVPASENPFKDKKPCKDKKPC   557.1212   5+                                    Geranylgeranyl neutral loss; methyl
  (H)ARNDPLLVGVPASENPFKDKKPCKDKKPC                                             696.1585                           4+         Geranylgeranyl, methyl                
  Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 (GBG2)     (F)REKKFFC                         486.261    2+                                    Methyl only
  Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 (GBG11)   (Y)IEERSGEDPLVKGIPEDKNPFKEKGSC     644.746    5+                                    Farnesyl neutral loss; methyl

###### Proteins from which C-terminal peptides were identified comparing predicted (Uniprot) vs found prenylation

  Protein   Prenylation (predicted)   Prenyl group(s) found   Peptide sequence (amino acid N-terminal to cleavage site in parentheses)   Methylated only found?   Expectation value(s)
  --------- ------------------------- ----------------------- -------------------------------------------------------------------------- ------------------------ -------------------------
  CN37      Farnesyl                  Farnesyl                (I)[HGSRKGGAMQIC]{.ul}                                                     Yes                      2.5e-7
                                      Geranylgeranyl          (Y)GKGKPVPIHGSRKGGAMQIC                                                                             8.2e-5
  LMNB1     Farnesyl                  Farnesyl                (H)[QQGAPRASNKSC]{.ul}                                                     Yes                      9.4e-8
  LMNB2     Farnesyl                  Farnesyl                (F)HQQGDPRTTSRGC                                                           No                       1.6e-6
  CDC42     Geranylgeranyl            Farnesyl                (L)[AALEPPEPKKSRRC]{.ul}                                                   No                       3.0e-7
                                      Geranylgeranyl          (L)[KNVFDEAILAALEPPEPKKSRRC]{.ul}                                                                   1.8e-11
  GBG 2     Geranylgeranyl            Geranylgeranyl          (F)REKKFFC                                                                 Yes                      1.2e-6
  GBG 3     Geranylgeranyl            Geranylgeranyl          (F)REKKFFC                                                                 No                       1.2e-6
  GBG 4     Geranylgeranyl            Geranylgeranyl          (F)REKKFFC                                                                 No                       1.2e-7
  GBG 5     Geranylgeranyl            Geranylgeranyl          (F)RPQKVCSFL                                                               No                       2.7e-7
  GBG 7     Geranylgeranyl            Geranylgeranyl          (L)LVGVPASENPFKDKKPC                                                       No                       5.4e-7
  GBG 10    Geranylgeranyl            Geranylgeranyl          (L)LGVPAGSNPFREPRSC                                                        No                       4.5e-5
  GBG 11    Farnesyl                  Farnesyl                (Y)IEERSGEDPLVKGIPEDKNPFKEKGSC                                             No                       4.1e-11
  GBG 12    Geranylgeranyl            Geranylgeranyl          (T)[SENPFKDKKTC]{.ul}                                                      No                       1.8e-9
  HRAS      Farnesyl                  Farnesyl                (L)RKLNPPDESGPGCMSCKC                                                      No                       see Fig S4 for spectrum
  RHO-G     Geranylgeranyl            Geranylgeranyl          (L)NPTPIKRGRSC                                                             No                       see Fig S3 for spectrum
  RHEB      Farnesyl                  Farnesyl                (L)[EAEKIDGAASQGKSSC]{.ul}                                                 No                       5.7e-6
  TP4A1     Farnesyl                  Farnesyl                (F)[KDSNGHRNNC]{.ul}                                                       No                       1.7e-6
  RAP1A     Geranylgeranyl            Geranylgeranyl          (N)[RKTPVEKKKPKKKSC]{.ul}                                                  No                       1.2e-5
  RAP2A     Farnesyl                  Farnesyl                (Y)AAQPDKDDPCCSAC                                                          No                       7.5e-5
  RAB3C     2x Geranylgeranyl         2x Geranylgeranyl       (L)KETPPPPQPNCGC                                                           No                       5.0e-7
  RAB7A     2x Geranylgeranyl         2x Geranylgeranyl       (L)DKNDRAKASAESCSC                                                         No                       2.9e-9
  RAB14     2x Geranylgeranyl         2x Geranylgeranyl       (L)TSEPQPQREGCGC                                                           No                       5.0e-7
  RAB5A     2x Geranylgeranyl         2x Geranylgeranyl       (R)GVDLTEPAQPARSQCCSN                                                      No                       2.1e-5
  RAB3A     2x Geranylgeranyl         2x Geranylgeranyl       (T)GAKQGPQLTDQQAPPHQDCAC                                                   No                       9.1e-12

All isoprene-modified peptides identified had long retention times (\>60 min) in 2-h liquid chromatographic separations on C18 silica-based resins, as expected given their hydrophobic character. Elution of the methylated, geranylgeranylated form of the M+4H+ peptide YGKGKPVPIHGSRKGGAMQIC (*m/z* 618.3604) from C18 occurred ([Fig 2](#F2){ref-type="fig"}*A*) at R~t~ = 86.1 min in a 118-min gradient from 10 to 40% acetonitrile. [Fig. 2](#F2){ref-type="fig"}*B* shows the MS/MS spectrum of this peptide, which underwent a facile loss of geranylgeranyl. The low mass region of the HCD spectrum ([Fig. 3](#F3){ref-type="fig"}) also shows characteristic fragments of the geranylgeranyl moiety at *m/z* 109.1, 123.12, 129.10, and 149.13, produced by fragmentation of the isoprene backbone ([@B21]). The fragments provided a convenient confirmation that spectra were of geranylgeranylated peptides and enabled detection of c-terminal peptides from Hras and from Rho G using the MS Filter utility available as part of the Protein Prospector package (see [Figs. S3 and S4](http://www.mcponline.org/cgi/content/full/RA120.001944/DC1)). The c-terminal peptide from myelin-associated 2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CN37) was identified farnesylated or geranylgeranylated. [Table I](#TI){ref-type="table"} presents a list of c-terminal modified peptides identified in a representative experiment showing the multiple types of modification on some c-termini. [Fig. 4](#F4){ref-type="fig"} shows a comparison of the retention times of two versions of a CN37 c-terminal peptide (both methylated and either farnesylated ([Fig. 4](#F4){ref-type="fig"}*B*) or geranylgeranylated ([Fig. 4](#F4){ref-type="fig"}*C*) detected in the same run. [Fig. 4](#F4){ref-type="fig"}*A* shows the extracted ion chromatogram of a peptide with a mass corresponding to a methyl only modification with an identical retention time to the geranylgeranylated peptide, suggesting that, in this case, the methylated, geranylgeranylated peptide underwent a neutral loss of geranylgeranyl in the source of the mass spectrometer.

![(*A*) Extracted ion chromatogram of YGKGKPVPIHGSRKGGAMQIC-methyl+geranylgeranyl+4 (*m/z* 618. 36; Rt = 86.11 min) derived from CN37; from LC-MS separation of chymotryptic peptides eluted with 10 m[m]{.smallcaps} DTT from thiopropyl Sepharose. The online reversed-phase column was eluted with a linear gradient composed of water and acetonitrile, each containing 0.1% formic acid from 10--40% acetonitrile. (*B*) HCD MS/MS spectrum of *m/z* 618.36. Major fragment ions detected in the spectrum (listed as fragment number: charge: mass) were: y2: +1: 249.13, b3:+1: 349.19, b5:+1: 534.34, b19-NH3:+3: 645.01, b19:+3: 650.69, b20:+3: 688.38, parent ion:+3: 733.39, y16:+2: 832.94, b19:+2: 975.53, parent ion:+2: 1099.59, y11:+1: 1121.56, y12:+1: 1258.61.](zjw0062061310002){#F2}

![Low mass region of the MS/MS spectrum presented in [Fig. 2](#F2){ref-type="fig"} showing fragments of the geranylgeranyl group generated as a result of its neutral loss during the HCD fragmentation process. The structures of these fragments were described by Hoffman and Kast (ref 21).](zjw0062061310003){#F3}

![Chromatographic behavior of CN37 c-terminal peptide GKGKPVPIHGSRKGGAMQIC modified by methyl (*top panel*), methyl + farnesyl (*middle panel*), or methyl + geranylgeranyl (*bottom panel*) in a single run. The retention time of the peptide in the *top panel* (labeled "methyl only") was almost identical to that of the geranylgeranyl/methyl-modified peptide in the *lower panel*. As pointed out in the text, the methyl only peptide was likely in this case generated by a loss of the geranyl group in the source of the mass spectrometer.](zjw0062061310004){#F4}

Prenylated c-terminal peptides were found from small guanine nucleotide binding proteins (GBG10, GBG11, GBG12, GBG7, GBG3, GBG4, GBG5), and [Table II](#TII){ref-type="table"} presents a list of all c-terminal peptides found to date along with their predicted (from Uniprot) and found prenylations. Peptides were also found from the Rab family of proteins known to be modified by the GGTase 2 enzyme (*i.e.* proteins containing two geranylgeranylated cysteines; see below). We determined from data collected in one of the four (see "Example of data from single capture with DTT and ACN elution from one of the four representative experiments separate chromatographic runs" under "Data Availability" for links to detailed data) representative experiments that of a total of 27 prenyl proteins whose peptides were identified (prenyl + non-prenyl), we were able to obtain high-quality MS/MS spectra on nine prenylated c-terminal peptides. Total prenyl protein counts require thorough examination of peptide sequence data as many Rab proteins, for example, have high sequence identity (see "Discussion" section).

In earlier analyses, we did not identify any c-terminal peptides from doubly geranylgeranylated peptides, even though we knew through detection of other, unmodified peptides from these proteins that we were enriching proteins that had this modification. Speculating that this may be due to them being very hydrophobic, we performed one more experiment. This time we analyzed the peptide mixture using a longer (155-min) gradient running from 20% to 60% acetonitrile; *i.e.* starting and ending at higher acetonitrile levels than usual. For this experiment, we also used a Fusion Lumos mass spectrometer equipped with EThcD to see if the different fragmentation was beneficial. Electron transfer dissociation has been shown to be particularly effective in the fragmentation of highly charged peptides, which many of the c-terminally prenylated peptides typically are ([@B22]). We found that the combined power of modified chromatographic conditions with the enhanced features of the Fusion Lumos instrument enabled detection of several c-termini from Rab proteins, including Rab3A, Rab3C, Rab5A, Rab7A, and Rab14. [Fig. 5](#F5){ref-type="fig"} shows the elution of the 18 amino acid- doubly geranylgeranylated c-terminal peptide (GVDLTEPAQPARSQCCSN+ 3H^+^) from Rab5A. The retention time of this peptide was 138.7 min in the 155min gradient. As shown in the accompanying MS/MS spectrum ([Fig. 5](#F5){ref-type="fig"}*C*), fragmentation produced exclusively b and c ions and showed a neutral loss of one of the two geranylgeranyl groups. Fragments of the isoprene similar to those seen in [Fig. 3](#F3){ref-type="fig"} were present in the low mass region of the spectrum, including a peak corresponding to the intact geranylgeranyl moiety at *m/z* 273.25.

![**Elution of GVDLTEPAQPARSQCCSN (M+3H+ = 807. 45) derived from Ras-related protein Rab-5A from analytical C18 column.** (*A*) Base peak chromatogram from 155-min 20--60% acetonitrile gradient run. (*B*) Extracted ion chromatogram showing (arrow) elution position of the peptide. (*C*) EThcD MS/MS spectrum showing b- and c-type ions representing fragments derived from the N terminus of the peptide listed here as in [Fig. 4](#F4){ref-type="fig"}: fragment:charge:mass. c3:+1: 289.15, b5:+1: 486.26, b6:+1: 615,30, c8:+1: 800.41, b9:+1: 911.45, c15:+2: 922.01, parent ion:+2: 1074.55, c11:+1: 1096.56, c13:+1: 1339.70, c14:+1, 1467.76, and low mass fragments (*inset*) derived from neutral loss of the geranylgeranyl isoprene (see legend to [Fig. 3](#F3){ref-type="fig"}. Geranylgeranyl also appears in an intact form in the spectrum at *m/z* 273.26).](zjw0062061310005){#F5}

DISCUSSION
==========

Despite their fundamental importance in cellular functions such as growth regulation, nuclear membrane structure/function, cytoskeletal rearrangement and cellular transport activities, global proteomic methods for characterization of prenylated proteins in unmodified cells and tissues have remained elusive. The current study describes a new approach that allows capture of isoprene-modified peptides and proteins for further biological characterization of these important membrane-interacting sequences. The method takes advantage of novel chemistry associated with the thioether linked isoprene at the c-terminus of prenylated species and its interaction with 2-thiopyridyl-protected thiopropyl groups attached to Sepharose. The resin-attached group represents a relatively hydrophobic surface apart from the hydroxyl group. It has been demonstrated that disulfide groups are hydrophobic and, in proteins, are generally located within the hydrophobic core ([@B23]). This coupled with the hydrophobic nature of the thiopyridyl ([@B24]) group provides a potential mechanism for the prenyl bind-and-release mechanism uncovered in this study. It is logical to assume that the capture process itself relies not only on the presence of the isoprene but also is likely influenced by the unique amino acid sequences that carry this modification. For example, although certain prenylated proteins were identified through peptide sequences with high confidence, their c-terminal sequences were not necessarily detected (*e.g.* Ras-related C3 botulinum toxin substrate 1; Uniprot ID P63001). Other variables in sample characterization are the chromatographic- and ionization behavior of individual peptides, which may in some cases limit detection. Determination of the exact number of prenyl proteins identified in chymotryptic digests is also complicated by the fact that subfamilies of closely-related Rab GTPase proteins have 75--90% sequence identity, sometimes confounding data interpretation ([@B25]). In fact, the latter proteins differ most in their c-terminal amino acid sequences.

The thiopropyl Sepharose resin used here is typically used to capture thiols through formation of disulfide bonds with the resin and was used by Forrester *et al.* to target palmitoylated peptides after chemical conversion of cysteine sulfur linked acyl palmitoylates to thiols in a method dubbed resin- assisted capture ([@B26]), which takes advantage of conventional bonding to the resin in contrast to the noncovalent interactions described here. Reduction of the disulfide in this study resulted in release of the thiopyridyl group and some isoprenylated peptides from the resin; further elution at low pH with 50% acetonitrile released more peptides. Results with a glutathione-modified thiopyridyl resin (glutathione is larger and more hydrophilic than the propyl group) were poor. Therefore, the chemistry at the resin surface including the presence of charged or polar groups undoubtedly plays a critical role in these phenomena. Although the exact mechanism of this interaction remains to be fully understood, further manipulation of the resin chemistry should provide more insight, perhaps even allowing enhanced performance.

Several interesting features emerged in the data (see [Tables I](#TI){ref-type="table"} and [II](#TII){ref-type="table"}). Peptides from CN37, a major protein component of the myelin membrane and from CDC42, a regulator of spindle microtubule attachment during mitosis and of cell polarity and migration, were found in high abundance during the analysis. c-terminal peptides from these proteins were found in both farnesyl and geranylgeranyl forms. The presence of both modifications is consistent with a report that RhoB exhibits similar flexibility in its preference for the two isoprenes ([@B27]). The data presented here provide clear evidence that CN37 and CDC42 are modified by either farnesyltransferase or GGTase I *in vivo*. We also found intermediate forms of the c-termini from CN37, CDC42, and guanine nucleotide binding proteins *i.e.* fully processed prenyl peptides with methyl ester modifications were found but also forms that were only prenylated. This is the first report to our knowledge of mixed prenylation of CDC42. The retention times of peptides on the C18 column demonstrated the difference in polarity conferred by the presence of a geranylgeranyl group *versus* a farnesyl ([Fig. 4](#F4){ref-type="fig"}). The meaning of the presence of both isoprenes on the same protein is still unclear at this point, although others ([@B28]) have speculated that the presence of farnesyl or geranylgeranyl may confer some specificity to membrane association, and it was reported that both CN37 isoforms could be labeled by either ^3^H farnesyl pyrophosphate or ^3^H geranylgeranyl pyrophosphate *in vitro* or in C6 cells after treatment with HMG Co A reductase inhibitors and labeling as above ([@B29]). RhoB was shown to be modified by both types of prenyl groups using a cell line that overexpressed the recombinant RhoB protein and labeling with ^3^H mevalonate ([@B30]). Subsequent reports ([@B31], [@B32]) detailed a gain of function for Rho-B after inhibition of farnesyl transferase (and subsequent geranylgeranylation of the molecule) in Rat1/ras transformed cells such that the geranylgeranylated molecule drove reversion of the transformed phenotype and inhibition of the cell cycle. Although the possible functional biological significance of mixed prenylation of CN37 and CDC42 is unknown at present, enrichment and analysis by LC-MS demonstrated in the current study opens the door to direct analysis of these phenomena in tissue samples. In addition to the mixed prenyl forms detected above, intermediate forms of targeted c-terminal peptides were detected. Isoprene-modified peptides were found with the AAX sequence removed but not methylated. In contrast with the recent report by Storck *et al.* ([@B19]), we only found two examples of CAAX box c-terminal peptides (one of which appeared in the peptides released from the resin by chymotryptic digestion alone; data not shown) with an intact CAAX sequences; with the exception of the guanine nucleotide binding protein subunit GBG5, the AAX sequence in captured peptides had always been removed by the Rce I enzyme. This difference may result from kinetic differences in prenyl protein processing between labeled samples in culture *versus* the more steady state represented by the tissue samples from mouse brain or simply differences in our capture techniques. Surprisingly, peptides with a methyl group present on the c-terminal cysteine and no prenylation were reported in the database search results. However, we believe that these were formed in each case from a neutral loss of the isoprene group in the source of the mass spectrometer based on their detection only when a prenylated equivalent was eluting. We observed this phenomenon primarily in the highly abundant peptides, suggesting that the neutral loss may not represent a major problem in prenylated peptide analysis using MS. However, altering instrument parameters to reduce the phenomenon, such as by lowering the temperature of the entry capillary into the instrument may be advisable, although this has not yet been tested. Beyond the neutral losses seen for prenyl groups on some peptides, MS/MS fragmentation of isoprene-modified peptides proceeded in a manner consistent with that expected from the unmodified peptides using the modes employed (*i.e.* HCD or EThcD) ([@B33]).

We detected c-terminal peptides from proteins recognized by the CAAX protein enzymes farnesyltransferase and GGTase I using HCD and in longer runs using EThcD c-terminal peptides from Rab-3a, Rab3c, Rab7a, Rab14, and Rab5a that were modified by two geranylgeranyl isoprenes (catalyzed by GGTase2) were identified. Many peptides from other Rab proteins were seen ([Table II](#TII){ref-type="table"}), suggesting that detection of these c-terminal peptides may also be achieved using higher starting acetonitrile in gradient elutions (20% *versus* 10%) coupled with enhanced fragmentation capability offered by EThcD for large peptides. Due to their size and hydrophobicity, the peptides from doubly geranylgeranylated c-termini migrated extremely late from the C18 column, even with the latter chromatographic adjustments, suggesting that alternate approaches (*e.g.* C4 or other more polar stationary phases) could help in separation and characterization of these peptides. Further experiments will help to define optimal combinations of the above.

It is attractive to imagine using this capture method for quantitation of prenylated species. We believe that its use for absolute quantitation of specific prenyl species will be challenging in the absence of internal standards or data regarding the amounts of particular proteins in the sample under study. However, use of the method in relative comparisons of prenylated proteins between samples should be possible given the proper use of internal standards. Such measurements might be particularly useful in tracking the relative amounts of a particular target protein under different metabolic conditions since the Rab proteins, for example, play a crucial role in cellular transport, cytoskeletal rearrangement, and other activities. An area in which relative quantitation might play an important role is in tracking the progress of infectious agents that are known to hijack host prenylation pathways ([@B34], [@B35]).

In summary, we developed a method that is capable of capturing prenylated proteins directly from tissue samples and that using high-resolution LC-MS coupled with customized informatics, we were able to identify and characterize tandem mass spectra from native c-terminal peptides derived from a range of these molecules for the first time. Guided by the current experiments, a combination of enhanced resin design with optimized chromatographic and mass spectrometric approaches should widen the range of peptides identified and characterized. This raises for the first time the possibility that changes in the prenylome of clinical samples or other noncultured cells and tissues can be directly assessed with minimal pre-processing.

DATA AVAILABILITY
=================

Data are available by accessing Protein prospector at the following URLs. Prenyl database searches (capture data from four different experiments):

<http://msviewer.ucsf.edu/prospector/cgi-bin/mssearch.cgi?report_title=MS-Viewer&search_key=fmto9gzzgz&search_name=msviewer>

<http://msviewer.ucsf.edu/prospector/cgi-bin/mssearch.cgi?report_title=MS-Viewer&search_key=znh6js2pye&search_name=msviewer>

<http://msviewer.ucsf.edu/prospector/cgi-bin/mssearch.cgi?report_title=MS-Viewer&search_key=qpacccy1ne&search_name=msviewer>

<http://msviewer.ucsf.edu/prospector/cgi-bin/mssearch.cgi?report_title=MS-Viewer&search_key=tyfc43dbja&search_name=msviewer>

Chymotryptic digest search

<http://msviewer.ucsf.edu/prospector/cgi-bin/mssearch.cgi?report_title=MS-Viewer&search_key=tdsjzt5yfd&search_name=msviewer>

Example of data from single capture with DTT and ACN elution from one of the four representative experiments (separate chromatographic runs):

DTT elution

<http://msviewer.ucsf.edu/prospector/cgi-bin/mssearch.cgi?report_title=MS-Viewer&search_key=znh6js2pye&search_name=msviewer>

ACN elution

<http://msviewer.ucsf.edu/prospector/cgi-bin/mssearch.cgi?report_title=MS-Viewer&search_key=ukgvnsmdvr&search_name=msviewer>

All LC-MS data associated with this study can be accessed through <https://massive.ucsd.edu> using access code MSV000085133.
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